Logo image
Targeting protein prenylation in progeria
Journal article   Peer reviewed

Targeting protein prenylation in progeria

Stephen G Young, Shao H Yang, Brandon S J Davies, Hea-Jin Jung and Loren G Fong
Science translational medicine, Vol.5(171), pp.171ps3-171ps3
02/06/2013
DOI: 10.1126/scitranslmed.3005229
PMCID: PMC3725554
PMID: 23390246
url
https://www.ncbi.nlm.nih.gov/pmc/articles/3725554View
Open Access

Abstract

A clinical trial of a protein farnesyltransferase inhibitor (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS) was recently completed. Here, we discuss the mutation that causes HGPS, the rationale for inhibiting protein farnesyltransferase, the potential limitations of this therapeutic approach, and new potential strategies for treating the disease.
Protein Prenylation - drug effects Humans Progeria - enzymology Enzyme Inhibitors - pharmacology Cell Nucleus Shape - drug effects Clinical Trials as Topic Progeria - genetics Enzyme Inhibitors - therapeutic use Progeria - drug therapy Farnesyltranstransferase - metabolism Animals Progeria - pathology Lamins - metabolism Farnesyltranstransferase - antagonists & inhibitors

Details

Metrics

Logo image